ACT BORTEZOMIB 3.5 MG — DIN 02438399
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG · TEVA CANADA LIMITED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ACT BORTEZOMIB?
ACT BORTEZOMIB 3.5 MG contains BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02438399, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 30-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT BORTEZOMIB used for?
Combination therapy for previously untreated multiple myeloma (suitable/unsuitable for SCT); progressive multiple myeloma after 1+ therapy; relapsed/refractory mantle cell lymphoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Bortezomib cost around the world?
Bortezomib is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 22 | 22 | ZAR███.██ |
| Australia | ex-manufacturer | 8 | 16 | AUD███.██ |
| Saudi Arabia | public | 15 | 16 | SAR███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Italy | ex-factory (classe H) | 10 | 12 | EUR███.██ |
| Romania | max producer price | 9 | 12 | RON███.██ |
| Czechia | max producer price (ex-factory) | 5 | 7 | CZK███.██ |
| Hungary | producer price (ex-factory) | 7 | 7 | HUF███.██ |
| Slovakia | categorised final price | 5 | 5 | EUR███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Bahrain | retail (max) | 2 | 2 | BHD███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 1 | NOK███.██ |
120 pack listings across 104 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Bortezomib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Bortezomib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Bortezomib, across 24 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TARO PHARMACEUTICALS INC | 3 | 2 | TARO-BORTEZOMIB | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 2 | 2 | BORTEZOMIB FOR INJECTION, BORTEZOMIB INJECTION | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | ACT BORTEZOMIB, BORTEZOMIB FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 4 | 1 | BORTEZOMIB FOR INJECTION | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 3 | 1 | BORTEZOMIB FOR INJECTION | Sourceable in Canada |
| APOTEX INC | 1 | 1 | BORTEZOMIB | Sourceable in Canada |
| JANSSEN INC | 1 | 1 | VELCADE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | BORTEZOMIB FOR INJECTION | Sourceable in Canada |
| PHARMASCIENCE INC | 1 | 1 | PMS-BORTEZOMIB | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 0 | BORTEZOMIB FOR INJECTION, BORTEZOMIB FOR INJECTION SDZ | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | BORTEZOMIB FOR INJECTION | No marketed DIN |
| GENERIC MEDICAL PARTNERS INC | 1 | 0 | BORTEZOMIB FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3.5 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; SUBCUTANEOUS |
| Pack configuration (monograph) | Individually cartoned 10 mL vials containing 3.5 mg of bortezomib. |
| Storage | Reconstituted solution may be stored at 25°C; must be administered within 8 hours of preparation. Store in original vial or syringe. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Bortezomib |
|---|---|
| ATC code | L01XG01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02438399 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2438399 |
| Brand name | ACT BORTEZOMIB |
| Generic / active ingredient | BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L01XG01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XG |
| Current status | MARKETED |
| Status date | 30-Dec-2020 |
| Original market date | 2015-11-17 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
1.3 mg/m2 BSA. Intravenous (1 mg/mL) as 3-5 sec bolus or Subcutaneous (2.5 mg/mL). Twice weekly for 2 weeks followed by rest. At least 72 hours between doses.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to bortezomib, boron or any excipients. Contraindicated for intrathecal administration (fatal events have occurred).
Warnings and precautions
Fatalities with overdosage. Serious risks: hypotension, cardiac disorders, hemorrhage (GI/intracerebral), severe motor neuropathy, and acute diffuse infiltrative pulmonary disease.
Is Bortezomib in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 24 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | APOTEX INC | MARKETED | 02456176 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | 02485257 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02423405 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02493306 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02452456 |
| BORTEZOMIB FOR INJECTION | 2.5 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02467003 |
| BORTEZOMIB INJECTION | 2.5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02550075 |
| PMS-BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | PHARMASCIENCE INC | MARKETED | 02466708 |
| TARO-BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | 02499061 |
| TARO-BORTEZOMIB | 2.5 MG | POWDER FOR SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | 02511932 |
2 · Same class — other molecules in ATC L01XG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Bortezomib | ACT BORTEZOMIB · BORTEZOMIB · BORTEZOMIB FOR INJECTION · BORTEZOMIB FOR INJECTION SDZ · +4 more | 24 | 12 | Yes |
| Carfilzomib | KYPROLIS | 3 | 3 | Yes |
| Ixazomib | NINLARO | 3 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XA | Carboplatin · Cisplatin · Oxaliplatin | 45 | 12 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XH | Romidepsin · Vorinostat | 2 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACT BORTEZOMIB called?
The same molecule, Bortezomib, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bortezomib Accord | Latin | Australia, Czechia, Iceland, Norway |
| Bortezomib Ever Pharma | Latin | Australia, Czechia |
| Bortezom | Latin | Australia |
| Bortezomib EPC | Latin | Saudi Arabia |
| BORTEZOMIB EUGIA | Latin | Australia |
| Bortezomib Juno | Latin | Australia |
| BORTEZOMIB MEDSURGE | Latin | Australia |
| BORTRACZO | Latin | Australia |
| DBL Bortezomib | Latin | Australia |
| Proteomib | Latin | Bahrain, Saudi Arabia |
| Bortada | Latin | Saudi Arabia |
| Bortezomib BOS | Latin | Saudi Arabia |
| Bortezomib Equity | Latin | South Africa |
| BORTEZOMIB FRESENIUS KABI | Latin | Czechia |
| BORTEZOMIB MSN | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.